SWKHL: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Revenue	32,230	-
Other revenue	536	-
Finance Receivables Segment-Operating Segments	-1,635	-
Operating Segments-Pharmaceutical Development And Other Segment	0	-
Corporate Non Segment	0	-
Benefit (provision) for credit losses	-1,635	-
Finance Receivables Segment-Operating Segments	0	-
Operating Segments-Pharmaceutical Development And Other Segment	209	-
Corporate Non Segment	0	-
Loss on impairment of intangibles assets	209	-
Interest expense	3,464	-
Finance Receivables Segment-Operating Segments	0	-
Operating Segments-Pharmaceutical Development And Other Segment	1,550	-
Corporate Non Segment	0	-
Pharmaceutical manufacturing, research and development expense	1,550	-
Finance Receivables Segment-Operating Segments	0	-
Operating Segments-Pharmaceutical Development And Other Segment	314	-
Corporate Non Segment	0	-
Loss on disposal of inventory	314	-
Finance Receivables Segment-Operating Segments	0	-
Operating Segments-Pharmaceutical Development And Other Segment	0	-
Corporate Non Segment	40	-
Depreciation and amortization expense	40	-
General and administrative expense	9,406	-
Other income (expense), net	1,657	-
Finance Receivables Segment-Operating Segments	0	-
Operating Segments-Pharmaceutical Development And Other Segment	0	-
Corporate Non Segment	4,220	-
Income tax expense	4,220	-
Net income	16,855	8,075
Provision (benefit) for credit losses	-1,635	-704
Loss on sale of assets	-82	-
Loss on impairment of intangible assets	209	0
Right-of-use amortization and cease use costs	143	112
Amortization of debt issuance costs	850	548
Deferred income taxes, net	4,156	2,266
Unrealized net gain on warrants	-2,563	77
Loss on disposal of inventory	314	-
Net gain from exercise and cancellation of warrants	0	0
Gain on sale of business	1,476	-
Change in fair value of acquisition-related contingent consideration	0	0
Loss from sale of assets	-	-82
Loss (gain) on revaluation of finance receivables	-3,727	-3,727
Foreign currency transaction gains	639	614
Loss on marketable investments	-314	-68
Loan discount amortization and fee accretion	5,961	2,956
Debt issuance costs	-	41
Interest paid-in-kind	1,582	826
Stock-based compensation	894	608
Depreciation and amortization expense	40	38
Interest, accounts receivable and other receivables	-207	-177
Foreign currency forward contract	-915	-915
Collateral returned for foreign currency forward contract	-2,750	-2,750
Other assets	-1,274	-850
Accounts payable, accrued expenses, and other non-current liabilities	-387	-871
Deferred income	-1,500	1,800
Net cash provided by operating activities	16,987	16,081
Proceeds from sale of property and equipment	110	110
Settlement of foreign currency forward contract	1,560	1,560
Proceeds from sale of assets and liabilities held for sale	6,790	-
Sale of marketable investments	0	0
Investment in finance receivables	28,500	23,500
Proceeds from sale of finance receivables	31,678	31,678
Repayment of finance receivables	34,651	33,141
Corporate debt securities principal payments	23	15
Purchases of property and equipment	512	163
Net cash provided by investing activities	45,800	42,841
Net settlement for employee taxes on stock options	-89	-89
Net payments on credit facility	-6,233	-5,939
Cash dividends	49,078	49,078
Payments of financing costs	41	-
Repurchases of common stock, including fees and expenses	3,067	1,737
Net cash used in financing activities	-58,508	-56,843
Net increase in cash and cash equivalents	4,279	2,079
Cash and cash equivalents at beginning of period	5,927	-
Cash and cash equivalents at end of period	10,206	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

SWKHL: the cashflow